Mouse model of devil facial tumour disease establishes that an effective immune response can be generated against the cancer cells

Frontiers in Immunology

Volumn 5, Issue MAY, 2014, Pages

  Pinfold, Terry L ^a   Brown, Gabriella K ^a   Bettiol, Silvana S ^b   Woods, Gregory M ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Devil facial tumour disease; Immunogenicity; Mouse model; Tasmanian devil; Transmissible cancer

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; INTERLEUKIN 10; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY ASSAY; DEVIL FACIAL TUMOR DISEASE; DOWN REGULATION; FACE TUMOR; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSURVEILLANCE; NONHUMAN; SPLEEN CELL; UPREGULATION;

EID: 84905365134     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00251     Document Type: Article

References (21)

1. Murchison EP, Schulz-Trieglaff OB, Ning Z, Alexandrov LB, Bauer MJ, Fu B, et al. Genome sequencing and analysis of the Tasmanian devil and its transmissible cancer. Cell (2012) 148(4):780-91. doi:10.1016/j.cell.2011.11.065
2. Jones ME, Paetkau D, Geffen E, Moritz C. Genetic diversity and population structure of Tasmanian devils, the largest marsupial carnivore. Mol Ecol (2004) 13(8):2197-209. doi:10.1111/j.1365-294X.2004.02239.x
3. Siddle HV, Kreiss A, Eldridge MDB, Noonan E, Clarke CJ, Pyecroft S, et al. Transmission of a fatal clonal tumor by biting occurs due to depleted MHC diversity in a threatened carnivorous marsupial. Proc Natl Acad Sci U S A (2007) 104(41):16221-6. doi:10.1073/pnas.0704580104
4. Siddle HV, Kaufman J. A tale of two tumours: comparison of the immune escape strategies of contagious cancers. Mol Immunol (2013) 55(2):190-3. doi:10.1016/j.molimm.2012.10.017
5. Murchison EP. Clonally transmissible cancers in dogs and Tasmanian devils. Oncogene (2008) 27(Suppl 2):S19-30. doi:10.1038/onc.2009.350
6. Murchison EP, Tovar C, Hsu A, Bender HS, Kheradpour P, Rebbeck CA, et al. The Tasmanian devil transcriptome reveals Schwann cell origins of a clonally transmissible cancer. Science (2010) 327(5961):84-7. doi:10.1126/science.1180616
7. Pearse AM, Swift K. Allograft theory: transmission of devil facial-tumour disease. Nature (2006) 439(7076):549. doi:10.1038/439549a
8. Siddle HV, Kreiss A, Tovar C, Yuen CK, Cheng YY, Belov K, et al. Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer. Proc Natl Acad Sci U S A (2013) 110(13):5103-8. doi:10.1073/Pnas.1219920110
9. Singh A, Qin H, Fernandez I, Wei J, Lin J, Kwak LW, et al. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma. J Control Release (2011) 155(2):184-92. doi:10.1016/j.jconrel.2011.06.008
10. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol (2000) 164(12):6166-73. doi:10.4049/jimmunol.164.12.6166
11. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol (1995) 13:151-77. doi:10.1146/annurev.iy.13.040195.001055
12. Kreiss A, Tovar C, Obendorf DL, Dun K, Woods GM. A murine xenograft model for a transmissible cancer in Tasmanian devils. Vet Pathol (2011) 48(2):475-81. doi:10.1177/0300985810380398
13. Brown GK, Kreiss A, Lyons AB, Woods GM. Natural killer cell mediated cytotoxic responses in the Tasmanian devil. PLoS One (2011) 6(9):e24475. doi:10.1371/journal.pone.0024475
14. Joyce S, Girardi E, Zajonc DM. NKT cell ligand recognition logic: molecular basis for a synaptic duet and transmission of inflammatory effectors. J Immunol (2011) 187(3):1081-9. doi:10.4049/jimmunol.1001910
15. Godfrey DI, Rossjohn J. New ways to turn on NKT cells. J Exp Med (2011) 208(6):1121-5. doi:10.1084/jem.20110983
16. Isakson PC, Pure E, Vitetta ES, Krammer PH. T-cell-derived B-cell differentiation factor(s) - effect on the isotype switch of murine B-cells. J Exp Med (1982) 155(3):734-48. doi:10.1084/jem.155.3.734
17. Kanai N, Min W-P, Ichim TE, Wang H, Zhong R. Th1/Th2 xenogenic antibody responses are associated with recipient dendritic cells. Microsurgery (2007) 27(4):234-9. doi:10.1002/micr.20342
18. Tangye SG, Ferguson A, Avery DT, Ma CS, Hodgkin PD. Isotype switching by human B cells is division-associated and regulated by cytokines. J Immunol (2002) 169(8):4298-306. doi:10.4049/jimmunol.169.8.4298
19. Salazar-Onfray F. Interleukin-10: a cytokine used by tumors to escape immunosurveillance. Med Oncol (1999) 16(2):86-94. doi:10.1007/bf02785841
20. Schulte S, Sukhova GK, Libby P. Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis. Am J Pathol (2008) 172(6):1500-8. doi:10.2353/ajpath.2008.070776
21. Azimzadeh A, Meyer C, Ravanat C, Cazenave JP, Wolf P. Xenograft rejection: molecular mechanisms and therapeutic prospects. Hematol Cell Ther (1996) 38(4):331-43. doi:10.1007/s00282-996-0331-2